We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
days to go: Expired investment: £616,916
Trecento Diagnostics, with the help of a molecular testing system complete, they are now ready to launch a patent-pending collection device named HygieCatch®. It is a non-invasive, needle-free examination, in the vet practice providing DNA extraction from urine onsite with a report within 40 minutes of extraction of the sample. The company has identified partners in the UAE and US and is also in early-stage discussions with UK vet practices.  Furthermore, for the purpose of commercialisation of HygieCatch & the technology used, alongside addition of new tests including Lyme disease the company is planning to raise its capital.  
days to go: Expired investment: £167,910
An end-to-end digital platform providing aesthetic medical treatment in a market valued at almost £76bn. NowMe work closely with customers throughout the process by discussing the treatment they desire, selecting an appropriate medical practitioner from a UK Clinic and offering available finance solutions. The company is raising funds to refine their product and secure IP, as well as cover working capital requirements. The firm plan to launch in 2018 and by 2025 achieve international leadership.
days to go: Expired investment: £172,790
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
Walsh Aviation Limited has plans to create a low altitude airborne data acquisition method using the latest in Gyroplane technology. They have a 20-20-20 target to be able to fly at an altitude of 20 meters above the vegetation canopy, with a speed of 20 knots and to provide the service profitably at £20 per line kilometre.   
days to go: Expired investment: £61,000
Improving urban mobility by offering a bike sharing service to reduce congestion and pollution whilst increasing physical activity. cycle.land has recently entered a partnership with Youon, the largest bike share company in China, to deliver their services all over Europe. The fleet will consist of regular bicycles, in addition to e-bikes, e-scooters and e-cars. cycle.land has also worked in conjunction with local councils, Transport for London and local boroughs to introduce dock less mobility companies in the UK.
days to go: Expired investment: £331,963
Velorution is an electrical cycling retailer with products designed for urban environments. They currently own 3 stores with a combined turnover of £500k. The company is raising funds to grow their business by increasing the number of permanent retail locations in 2019. In addition, they are planning to increase brand awareness by partnering with other businesses. Current collaborations include Selfridges and Lululemon, where Velorution cycles are showcased at their concessions and pop-up venues.
days to go: Expired investment: £543,090
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph